The audience for this course is limited to clinicians who wish to provide HIV treatment or who are currently providing treatment. This includes physicians, nurse practitioners, physician assistants, pharmacists, nurses and dentists.

This extensive three day HIV clinical training program consists of two virtual didactic days on Monday and Tuesday, March 3 and 4 and one in-person clinical training day on Wednesday, Thursday, Friday March 12, 14, 14,  or Monday, Tuesday, Wednesday, March 17, 18, 19, 2025.

On the first two days will be virtual and feature expert faculty who will discuss cutting-edge HIV topics such as outpatient management, antiretroviral use, clinical use of resistance assays, and co-morbidities (including Hepatitis C, cardio vascular disease and STIs) management of women, perinatal transmission, psychosocial, substance use and legal issues. 

The third day will be in -person on one of the six days listed above from 8:30 am to 4:00 pm. . The in person observation will be spent in Drexel University College of Medicine’s Division of Infectious Diseases and HIV Medicine HIV service, Partnership Comprehensive Care Practice.

Questions:  Call Tiania Warner 215.246.5298

CME Program Code: 22251

LEARNING OBJECTIVES: Participants will be able to:

• Describe the medical management of HIV
• Discuss what medications to initiate and the role of resistance testing
• Identify legal parameters that need to be met when providing HIV testing or care
• Recognize treatment options for HCV in the patient with HIV
• Describe HIV testing technology and HIV testing and special issues in treating adolescents
• Discuss the role of nPEP/PrEP in HIV care
• Identify cardiovascular complications of HIV and their ramifications for treatment
• Differentiate care issues unique to women
• Illustrate nutritional challenges for patients with HIV
• Examine the interaction of STIs on the treatment and prevention of HIV infection
• Examine trauma informed care as a way to address stigma and retention in care
• Explain the role of medically assisted treatments for patients with substance use disorder
• Explain strategies to address nicotine addiction and assist smokers in quitting

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Drexel University College of Medicine and the MidAtlantic AIDS Education and Training Center of the Health Federation of Philadelphia. The Drexel College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

AMA Credit Designation Statement: The Drexel University College of Medicine designates this live activity for a maximum of 14.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AOA: This program is eligible for 14.00 credits in Category 2A of the American Osteopathic Association.

• Individuals in a position to control the content of this educational program are required to disclose all relevant financial relationships with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Any relevant financial relationships must be mitigated by ANAC prior to the presentation and announced to the audience. Presenters will announce any disclosures prior to their educational session. NCPD planning committee members Julie Schexnayder, DNP, PhD, MPH, ACNP-BC, Kristin Walker RN, MSN, CNM, and Lane Taylor MPH have no relevant financial relationships with ineligible companies to disclose.

FACULTY DISCLOSURE STATEMENT

It is the policy of Drexel University College of Medicine to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational programs. Speakers at continuing medical education activities are required to disclose to the audience, any relevant commercial interest (which is any entity producing, marketing, re-selling or distributing health care goods or services consumed by or used on patients). Any conflicts of interest must be resolved prior to the presentation and announced to the audience. The intent of this disclosure is to allow participants to form their own judgments about the educational content of this activity and determine whether the speaker’s commercial interests influenced the presentation. In addition, speakers are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in their presentation.

FACULTY DISCOSURES: David Koren, PharmD, BCPS, AAHIVP is on the advisory committee for Gilead Sciences, ViiV and Thera Technologies, He also disclosed, he is an independent contractor for Thera Technologies and Abbvie. Joanne Gilmore, MSN, CRNP is on the speaker’s bureau for Gilead Sciences and Abbvie. Roberta Laguerre, MD is on the speaker’s bureau for Gilead Sciences. Helena Kwakwa, MD, MPH, institution has received a grant from ViiV. They attest that clinical recommendations are evidence based and free of commercial bias. Amy Althoff, MD, Lenore Asbel, MD, Ellen Tedaldi MD, Margaret Cauterucci, RD, Leah McCurdy MSN, CRNP, FNP-C, RN-BC, Yolanda French Lollis, Esq., and Marcy Witherspoon, MSW, LSW have no commercial relationships to disclose.

PLANNING COMMITTEE DISCLOSURES: Jennifer Kolker, MPH, Amy Althoff, MD have no relationships to disclose.

Requirements to receive credits: Continuing education credits will be awarded to those who registered for the program, attend the entire program, complete the discipline-specific requirements and program evaluation.

ACKNOWLEDGEMENT:

Supported by a grant from the Health Resources and Services Administration (HRSA),

HIV/AIDS Bureau, Office of Program Support, No. U1OHA29295

Intended Audience

Clinicians who wish to provide HIV treatment or who are currently providing treatment.

Contact